Introduction
The transcription factor p53 exerts a pivotal role in controlling cell cycle progression and apoptosis in response to various forms of genotoxic and cellular stress (Anderson and Appella, 2004) . Although normally existing in a latent state, stress conditions cause p53 to become activated, allowing transcriptional modulation of a large body of genes. Mice engineered to lack p53 expression have a high propensity for development of a broad spectrum of tumors (Donehower et al., 1992) . In humans, altered p53 regulation is a common step along the pathway of tumorigenesis with B50% of human cancers showing mutation of the TP53 gene, often a loss of one gene copy and a point mutation within the second. p53 overexpression is also deleterious with heightened p53 levels during development causing organ atrophy (Nakamura et al., 1995; Godley et al., 1996; Allemand et al., 1999) . One hypermorphic p53 mutant, although decreasing the susceptibility to tumor development, results in reduced longevity (Tyner et al., 2002 ). Control of the intracellular level of p53 therefore represents a critical feature for maintenance of normal cell proliferation and life span. p53 activity is regulated by various means, including protein turnover. Stability of p53 is primarily mediated by the mouse double minute 2 (Mdm2) gene product . Mdm2 (also known as Hdm2 in humans), an E3 ubiquitin ligase, directly interacts with and ubiquitinates p53, promoting its cytoplasmic degradation through the 26S proteasome (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Freedman and Levine, 1998; Roth et al., 1998) . Mdm2 also regulates p53 by binding and occluding its Nterminal transactivation domain (Momand et al., 1992; Oliner et al., 1993) . Evidence is emerging that p53 is also targeted by other ubiquitin ligases, including COP1 (Dornan et al., 2004) , Pirh2 (Leng et al., 2003) , ARF-BP1/Mule and p300 (Grossman et al., 2003) , and by ubiquitin-specific proteases such as HAUSP (Li et al., 2002 (Li et al., , 2004 , although the regulation of these enzymes is less clear.
Exposure to various stress stimuli cause alterations in the p53 modification state that facilitate loss of association with Mdm2, leading to higher p53 levels. In response to genotoxic stress, for example, p53 Nterminal sites are targeted by members of the phosphatidylinositol 3-kinase-like kinase (PIKK) family, including ATM, ATR and DNA-PK, as well as downstream effector kinases Chk1 and Chk2 (Anderson and Appella, 2004; Bode and Dong, 2004) . Such modifications both reduce p53 proteolytic degradation and increase the accessibility of the transactivation domain, among other effects. Activation of these kinases also leads to heightened Mdm2 auto-ubiquitination and Mdm2 destabilization (Stommel and Wahl, 2004) . The importance of Mdm2 in appropriately regulating p53 is demonstrated both by the lethality of Mdm2-null mice and the fact that viability can be rescued by simultaneous deletion of the p53 gene (Jones et al., 1995; Montes de Oca Luna et al., 1995) . In addition, a hypomorphic allele of Mdm2 exhibits increased p53 transcriptional activity and apoptosis in homeostatic tissue (Mendrysa et al., 2003) . In humans, overexpression of Hdm2 is common in a variety of different tumor types, particularly in soft tissue tumors and osteosarcomas, that express wild-type (wt) p53 (Momand et al., 1998) . These data attest to the conclusion that Mdm2 levels, like those of p53, must be exquisitely controlled.
A number of factors that alter the p53-Mdm2 circuitry have been identified. One prominent member of this group is the ARF tumor suppressor (p14ARF in humans, p19ARF in mice) (Lowe and Sherr, 2003) . Oncogene overexpression increases ARF levels (de Stanchina et al., 1998; Palmero et al., 1998; Radfar et al., 1998; Zindy et al., 1998) and stimulates ARFMdm2 complex formation Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . This in turn causes a decrease both in Mdm2 auto-ubiquitination (indicative of reduced ubiquitin ligase activity) and in the ubiquitination of p53, thus stabilizing p53. Nevertheless, the increase in p53 levels in response to oncogene expression is only partially abrogated in ARF-null cells (de Stanchina et al., 1998; Zindy et al., 1998) and, in certain tumorigenesis models, p53 upregulation following oncogenic stress does not involve ARF (Tolbert et al., 2002; Verschuren et al., 2002) . Thus, ARF-independent pathways that stimulate p53 in response to hyperproliferative signals surely exist. A number of Mdm2-interacting proteins that regulate the degradation of p53 have recently come to light, including the tumor susceptibility gene 101 (TSG101 (Li et al., 2001) ), the retinoblastoma protein (Rb (Hsieh et al., 1999) ) and the transcription factor Yin Yang 1 (YY1 (Gronroos et al., 2004; Sui et al., 2004) ). Nucleolar proteins are also prominent among this group, including the ribosomal proteins L5, L11 and L23 (Lohrum et al., 2003; Zhang et al., 2003; Bhat et al., 2004; Jin et al., 2004) , and nucleophosmin (also called B23 (Kurki et al., 2004) ), the latter protein also able to bind and inhibit ARF (Itahana et al., 2003; Bertwistle et al., 2004; Korgaonkar et al., 2005) . A role for the nucleolus in the regulation of p53 has recently become apparent with nucleolar disruption leading to p53 stabilization (Rubbi and Milner, 2003; Olson, 2004) . ARF has been found to sequester Mdm2 in the nucleolus (Weber et al., 1999) , although this activity does not appear to be requisite for ARF-dependent p53 stabilization (Llanos et al., 2001; Korgaonkar et al., 2002) .
Another prominent nucleolar phosphoprotein is nucleolin (also called C23 (Ginisty et al., 1999; Srivastava and Pollard, 1999) ), an abundant c-Mycinduced gene product (Greasley et al., 2000) . In response to c-Myc or a heightened cellular proliferation rate, nucleolin levels can increase B4-fold (Sirri et al., 1997; Greasley et al., 2000) . Nucleolin functions at an early step in precursor ribosomal RNA (rRNA) processing (Ginisty et al., 1998; Borovjagin and Gerbi, 2004) , and disruption of nucleolin homologs in yeast cause unbalanced production of the large and small ribosome subunits (Kondo and Inouye, 1992; Lee et al., 1992; Gulli et al., 1995) . Although the yeast strains lacking expression of the homologs are viable, they show severe defects in growth, strongly suggesting that knockouts (ko) of the mammalian protein will be lethal. Nucleolin has stress-regulated interactions with numerous mRNA molecules (Yang et al., 2002) , and regulates the turnover of particular mRNAs, including those encoding the apoptosis inhibitor Bcl-2 and the cell-cycle regulatory factor gadd45a (Sengupta et al., 2004; Zheng et al., 2005) . Recently, nucleolin has been found to inhibit translation of the p53 message following DNA damage (Takagi et al., 2005) . Nucleolin is also directly involved in the transcriptional regulation of various genes, including rRNA (Bouche et al., 1984; Egyhazi et al., 1988) . In response to heat shock or genotoxic stress, nucleolin serves to inhibit chromosomal DNA replication by binding and repressing replication protein A (RPA) (Daniely and Borowiec, 2000; Wang et al., 2001; Kim et al., 2005) , the cellular single-stranded DNAbinding protein. These stresses also cause a fraction of the nucleolin pool to relocalize from the nucleolus to the nucleoplasm in a reaction stimulated by physical interaction with p53, but independent of the ability of p53 to activate transcription (Daniely et al., 2002) . Together, these data indicate that nucleolin globally modulates DNA and RNA metabolism following stress.
Here we examine the effect of nucleolin on the p53-Hdm2 regulatory loop. We find that nucleolin stabilizes p53 by binding and inhibiting Hdm2. Although the effects of nucleolin mimic those seen previously for ARF, nucleolin can exert these effects in cells lacking ARF expression. Because nucleolin levels are increased by proliferative signals, we propose that nucleolin acts in a pathway parallel to ARF to increase p53 levels in response to oncogenic stress.
Results

Nucleolin modulates p53 levels in vivo
To understand the significance of the previously identified nucleolin-p53 interaction (Daniely et al., 2002) , we characterized the effect of nucleolin on p53 protein levels in cells that normally express wt p53 (U2-OS, HCT116-wt) or in p53-null cell lines (H1299 or HCT116-ko) transfected with wt p53. In contrast to H1299 cells, both U2-OS and HCT116 cells lack detectable expression of ARF (Park et al., 2002) , and these expression patterns are not altered by nucleolin (data not shown). In the current study, we employ tagged-nucleolin constructs which have properties that are identical to those of endogenous nucleolin, including intracellular localization and ability to associate with RPA following genotoxic stress (Kim et al., 2005) . Transfection of U2-OS cells with increasing levels of a plasmid expressing green fluorescent protein (GFP)-tagged nucleolin (GFPNu) was found to raise p53 levels nearly fourfold relative to mock-transfected cells and nearly to the level of p53 found in cells treated with proteasome inhibitor MG132 (Figure 1a ). There was an B2-fold increase in total nucleolin protein at the highest levels of nucleolin-vector transfected (data not shown; see Figure 7a ), indicating that the effects on p53 levels are not a result of extreme nucleolin overexpression. Transient or stable expression of nucleolin increased the level of p53 in other cell lines, including HCT116-wt cells (Figure 1b) . Expression of nucleolin tagged with cMyc or Flag epitopes instead of GFP resulted in similar increases in p53 levels ( Figure S1 and data not shown). Our data demonstrate that nominal increases in nucleolin expression significantly elevate p53 levels in unstressed cells. Takagi et al. (2005) have observed that nucleolin can inhibit p53 translation by binding to an element in the 5 0 untranslated region of the p53 message. We do not observe repressive effects of nucleolin on p53 protein levels, except when high amounts of the nucleolin overexpression vector are transfected (data not shown). Under our conditions which employ moderate levels of nucleolin, the translation repression mechanism does not appear to play a major regulatory role.
It is possible that even a slight increase in nucleolin expression results in genotoxic stress, leading to p53 activation and stabilization. A hallmark of human p53 activation is phosphorylation of Ser15 by members of the PIKK family. Testing the status of Ser15, nucleolin increased the total p53 level by twofold, and the level of pSer15-p53 remained unaltered (Figure 1c , lanes 1 and 3; see also darker exposure). A parallel increase in endogenous p21 cip1/waf1 protein levels was also observed (additional p53-downstream targets are examined in more detail below). In contrast, when cells transfected with GFPc (empty vector) or GFPNu were treated with the DNA-damaging agent camptothecin (CPT), similar increases in both the total and pSer15-p53 were noted (lanes 2 and 4). These data indicate that nucleolin increases p53 levels in a pathway, at least in part, distinct from that utilized by cells undergoing genotoxic stress.
Downmodulation of nucleolin reduces p53 levels
To more clearly show that nucleolin causes coordinate changes in the level of p53, we employed two different nucleolin-specific short-interfering RNA (siRNA) molecules, siNu1 and siNu2, to downmodulate nucleolin levels. At 24 h post-transfection, both siNu1 and siNu2 molecules reduced the amount of nucleolin protein to 20 and 40%, respectively, of that observed in cells treated with a control siRNA molecule directed against luciferase (siLuc) (Figure 2a ; compare lanes 2 and 5 with lane 1). Control experiments found that the level of nucleolin in untransfected cells was similar to that detected in siLuc-treated cells (compare lanes 1 and 8). Reductions in the amount of p53 comparable to that of nucleolin were observed when p53 was examined by Western blotting (Figure 2a ). Similar effects were seen by immunofluorescence microscopy ( Figure 2b ). Using either siRNA molecule, cells with reduced nucleolin staining were also found to be deficient in p53. No overt changes in the localization of the residual p53 were noted and cell morphology remained apparently normal during the course of the experiment. At late times posttransfection (>72 h; data not shown), as the level of nucleolin returned to more normal levels, the relative increase of p53 was found to be slightly higher than that observed for nucleolin. p21 cip1/waf1 protein levels were also increased and a significant amount of death was noted. As nucleolin downmodulation appears to be somewhat toxic to cells, we postulate that this stress is responsible for the relative increase in p53 protein levels. A reduction in translational repression of the p53 message by nucleolin is also possible (Takagi et al., 2005) . Overall, we find that alterations in the level of nucleolin cause parallel changes in the amount of p53 protein. Figure 1 Nucleolin overexpression increases p53 protein levels. Lysates were prepared from (a) U2-OS cells that were transiently transfected with increasing levels of a nucleolin-expression plasmid (GFPNu; 0.3 and 0.6 mg in a six-well plate), or from (b) HCT116-wt cells that were either transiently or stably transfected with the GFPNu or GFPc (empty vector) plasmids, as indicated. When required, cells were treated with 30 mM MG132 for 4 h to inhibit the proteasome. Lysates were then subjected to SDS-PAGE and Western blotting with antibodies against GFP (to reveal GFPnucleolin), p53 and b-actin, the latter as a loading control. These experiments show that nucleolin expression increases p53 protein levels. (c) U2-OS cells were transiently transfected with either GFPc or GFPNu expression vectors. As indicated, cells were treated with 2 mM CPT for 90 min to cause DNA damage. The lysates were blotted for p53 phosphorylated on Ser15 (pS15-p53), total p53 (p53), p21 cip1/waf1 , GFP and b-actin. In this panel, note that the anti-GFP antibody recognizes GFP in lanes 1 and 2, and GFP-nucleolin in lanes 3 and 4. To conserve space, the appropriate bands from the Western blot were spliced into a single panel. The relative amount of p53 was calculated after correction for the amount of b-actin.
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Nucleolin regulates the half-life of p53 Because p53 levels are primarily governed through the regulation of p53 stability, we examined the influence of nucleolin on the p53 protein half-life. Following transfection of HCT116-wt cells with either GFPNu or GFPc expression vectors, cells were treated with cycloheximide and then harvested at various times post-treatment. Probing the lysates for p53 protein levels indicated a longer p53 half-life in cells expressing GFP-nucleolin ( Figure 3a ). Densitometric analysis of the p53 levels, corrected for the level of b-actin in the same sample, confirmed this result (Figure 3b ). In contrast, knockdown of nucleolin did not show any obvious destabilization of p53, compared to use of control siRNA molecules (data not shown), perhaps suggesting that nucleolin might use additional mechanisms to control p53 levels (see above). In sum, our data indicate that heightened nucleolin expression results in significant stabilization of the p53 protein.
Nucleolin inhibits Hdm2-mediated ubiquitination of p53 in vivo and in vitro The primary pathway of p53 turnover involves ubiquitination by Hdm2 and subsequent proteasomal degradation. Because our data suggest that nucleolin might interfere with this pathway, we examined the effect of Hdm2 on the ability of nucleolin to modulate p53 levels. We observed that nucleolin had a more pronounced effect on p53 levels in U2-OS cells expressing ectopic Hdm2 (Figure 4a ). In the absence of exogenous Hdm2, nucleolin stimulated p53 levels B2-fold ( Figure 4a , lanes 8-11, compare to lane 1). Expression of Hdm2 by itself reduced the amount of p53 (lane 2), and ectopic nucleolin expression in these cells increased the amount of p53 by B4-fold over these lower levels (lanes 4-7; compare to lane 2). Unexpectedly, we also observed that nucleolin caused a marked reduction in the total level of Hdm2 (compare lane 7 to lane 2). This effect is studied in more detail below. Use of p53-null H1299 cells that were transiently transfected with p53 ( Figure 4b ) again found that nucleolin caused a more significant p53 increase in cells also expressing ectopic Hdm2 (3.9-fold, compare lane 8 to lane 4). The greater effect of nucleolin on p53 levels in the presence of Hdm2 suggests that nucleolin inhibits Hdm2. If nucleolin did not act through Hdm2, nucleolin would be expected to cause a similar fold increase of p53 in the presence or absence of Hdm2, even if the absolute levels of p53 differed. were stained with anti-nucleolin and p53 antibodies, and visualized by epifluorescence microscopy. Identical exposure times were used. Both the initial depletion of nucleolin protein and its subsequent recovery caused parallel changes in p53 levels. Note that downmodulation of nucleolin did not result in any obvious nucleolar disruption.
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To test this hypothesis, we characterized the effect of nucleolin on the Hdm2-mediated ubiquitination of p53 ( Figure 5a ). In U2-OS cells, as expected, expression of ectopic Hdm2 resulted in the accumulation of polyubiquitinated p53 (lower panel, lane 2), which was further heightened by treatment with MG132 (lane 3). Strikingly, co-expression of nucleolin diminished p53 polyubiquitination, particularly at the higher nucleolin levels, and led to the formation of putative mono-and di-ubiquitinated p53 (lanes 4-5). Loss of the residual polyubiquitinated p53 at the higher levels of nucleolin correlated with an increase in the amount of p53. Interestingly, the inhibition of ubiquitination was persistent even in the presence of proteasomal inhibitor (lane 6). A similar loss of p53 polyubiquitination was observed in H1299 cells following high nucleolin expression, even after MG132 treatment ( Figure 5b , lower panel), and, to a lesser extent, in HCT116-wt cells that expressed both endogenous p53 and exogenous flag-tagged p53 ( Figure 5c , lower panel, compare lane 3 to lane 1). Control experiments found that nucleolin did not appreciably alter the overall pattern of protein ubiquitination (data not shown). Hdm2 protein levels were diminished with ectopic expression of GFPNu compared to GFPc in U2-OS, H1299 and, to a lesser extent, HCT116wt cells (Figure 5a -c). Our evidence indicates that nucleolin selectively disrupts p53 ubiquitination by Hdm2, resulting in p53 stabilization and an increase in cellular p53.
To provide direct evidence that nucleolin affects p53 ubiquitination, we utilized an in vitro reconstitution system for p53 ubiquitination by Hdm2, using purified proteins (Wang et al., 2002) . This system catalysed robust p53 ubiquitination in an Hdm2-dependent reaction ( Figure 5d ; lane 2). While purified nucleolin had no effect on p53 modification in the absence of Hdm2 (lane 3), the addition of increasing amounts of nucleolin to Hdm2 dramatically reduced p53-ubiquitination (lanes 4 and 5). These results demonstrate that nucleolin inhibits Hdm2-mediated ubiquitination of p53 in vivo and in vitro.
p53 stability is governed by a balance between action of various E3 ubiquitin ligases, including Hdm2 (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Freedman and Levine, 1998; Roth et al., 1998) , COP1 (Dornan et al., 2004) , Pirh2 (Leng et al., 2003) and ARF-BP1/Mule , and ubiquitinspecific proteases that remove this post-translational modification (e.g., HAUSP (Li et al., 2002 (Li et al., , 2004 ). To provide additional evidence that nucleolin is not a general inhibitor of p53 ubiquitination, we tested HeLa cervical carcinoma cells. HeLa cells are transformed by human papillomavirus (HPV) type 18 and express the HPV E6 oncoprotein which, in conjunction with the cellular E6-associated protein (E6-AP; an E3 ubiquitin ligase), ubiquitinates p53 and destines it for proteolytic degradation (Wsierska-Gadek and Horky, 2003) . Overexpression of nucleolin in these cells had no significant effect on either p53 levels or the p53 ubiquitination state (Figure 5e , lane 3), as compared to the empty vector control (lane 2). These data indicate that nucleolin does not inhibit p53 modification by E6/E6-AP. These data also lead to the conclusion that nucleolin does not have an associated ubiquitin protease activity similar to that of HAUSP (Li et al., 2002 (Li et al., , 2004 , as such activity would be expected to cause a loss of polyubiquitinated p53. We also tested the effect of nucleolin overexpression on the ability of p300, a putative E4 ubiquitin ligase for p53 (Grossman et al., 2003) , to degrade p53. Nucleolin had no effect on p300 levels and was unable to prevent the dimunition in p53 levels caused by p300 (data not shown). We conclude that the effect of nucleolin is specific for Mdm2.
Nucleolin associates with Hdm2 and inhibits the Hdm2 ubiquitin ligase activity The inhibition of p53 ubiquitination could be a consequence of nucleolin binding to the C-terminal regulatory region of p53 (Daniely et al., 2002) , which contains multiple lysines that are ubiquitination targets (Rodriguez et al., 2000) , and hence sterically block Hdm2 action. Alternatively, nucleolin might directly bind Hdm2 and thereby alter its ability to modify p53. As a first test of this hypothesis, we tested the interaction of endogenous nucleolin and Hdm2 in co-immunopre- , lanes 3 and 6). We consistently observe a slightly higher level of nucleolinHdm2 complex in H1299 cells as compared to U2-OS cells, even though the latter cell line has more endogenous Hdm2 protein ( Figure S2 ). As mentioned, inhibition of p53-ubiquitination was also found to be more striking in H1299 cells than in U2-OS cells ( Figure  5a and b, above). While these differences may merely be a consequence of the use of two different cell types, we note that H1299 cells are p53-negative/ARF-positive, Figure 5 Nucleolin inhibits Hdm2-mediated p53 ubiquitination in vivo and in vitro. (a) U2-OS, (b) H1299 and (c) HCT116-wt cells were transfected with 3 Â -Flag p53 (15 ng), Hdm2 (300 ng), Ub-His (150 ng) and GFPNu (600 and 900 ng for U2-OS; 900 ng for H1299 and HCT116-wt) plasmids. The His-tagged (ubiquitinated) species were then immunoprobed for the presence of p53. Total lysates were probed for GFP (i.e., nucleolin), p53 (total), Hdm2 and b-actin. In U2-OS cells, with increasing nucleolin expression, higher molecular weight species of p53 were reduced significantly, even in the presence of proteasomal inhibitor (panel a, lane 6). A similar loss of p53 poly-ubiquitination was observed with H1299 cells (panel b) and, to a lesser extent, in HCT116-wt cells (panel c). (d) In vitro p53 ubiquitination was carried out as described in Materials and methods, in the presence of increasing amounts of GST-nucleolin (1-5 ng) purified from yeast. Ubiquitinated p53 was visualized by immunoblotting with a p53-specific monoclonal antibody (DO-1). (e) HeLa cells were transfected with 3 Â -Flag p53 (25 ng), Ub-His (250 ng) and either GFPNu (1 mg) or GFPc vector (0.5 mg) plasmids. Cells were treated with 30 mM MG132 for 4 h. The His-tagged (ubiquitinated) species were isolated and then immunoprobed for the presence of p53. Total lysates were probed for GFP (i.e., GFP or GFP-nucleolin), p53 (total) and b-actin. Nucleolin overexpression did not inhibit p53 ubiquitination in HeLa cells, which is predominantly regulated by HPV E6.
while U2-OS cells are p53-positive/ARF-negative. Finally, we examined the ability of purified glutathione-Stransferase (GST)-Hdm2 to interact with nucleolin in lysates from HCT116-wt or -ko cells. Following incubation of GST-Hdm2 or GST alone with lysates, analysis of the complexed material found that nucleolin bound GST-Hdm2 (Figure 6e , lanes 3 and 4) but did not detectably associate with GST alone (lanes 1 and 2) . We did not discern any influence of p53 on the ability of nucleolin to bind Hdm2 in this assay. We are currently examining the interactions between p53, Hdm2 and nucleolin using purified components to more directly test the possibility that p53 inhibits nucleolin-Hdm2 association. In sum, these data indicate that nucleolin and Hdm2 can complex in vivo and in vitro in a p53-independent manner.
The ability of nucleolin and Hdm2 to physically interact suggests that nucleolin might inhibit the Hdm2 ubiquitination activity directly, thereby explaining the effect of nucleolin on p53 modification. To test this possibility, we examined Hdm2 auto-ubiquitination as an indicator of its overall ubiquitin ligase activity. In H1299 cells transfected with Hdm2 and His-tagged ubiquitin (Ub-His), a significant level of ubiquitinated Hdm2 was observed (Figure 7a, lane 4) . When these cells were cotransfected with increasing levels of nucleolin, the level of ubiquitinated Hdm2 and total Hdm2 (n.b., the ubiquitinated proteins were not isolated in this experiment) progressively declined (lanes 5 and 6). At the highest level of nucleolin, ubiquitinated Hdm2 was barely detected (lane 6). Note that this level corresponds to only an B2-fold increase in total Figure 6 Nucleolin and Hdm2 interact in vivo and in vitro. Lysates from non-transfected p53-wt (U2-OS, SJSA) and p53-null (H1299) cells, as indicated, were subjected to immunoprecipitation using (a) two different antibodies against Hdm2 (Ab-1 and SMP14), control IgG or (b) anti-nucleolin antibodies. The immunoprecipitates were subjected to Western analysis using anti-nucleolin, Hdm2, or bactin antibodies. These data indicate that endogenous nucleolin and Hdm2 associate in a p53-independent manner. (c) U2-OS or H1299 cells were mock-transfected (Cont), or transfected with the empty GFPc (vec) or GFP-nucleolin (nucleolin) vectors, as indicated. (d) Similarly, U2-OS or H1299 cells were mock-transfected (no DNA control; 'À'), or transfected with the empty Flag and GFP vectors (vec), or GFPNu (nuc) and Flag-Hdm2 (hdm2) vectors. Aliquots of the resulting lysates were subjected to immunoprecipitation with anti-Hdm2 (panel c), or anti-Flag (panel d) antibodies. The immunoprecipitates, or aliquots of the original lysates, were immunoblotted with antibodies directed against nucleolin, Hdm2, the GFP or Flag tags, and b-actin. 'ns' indicates a nonspecific band. These data indicate that endogenous and exogenous nucleolin and Hdm2 associate in a p53-independent manner. We note that control experiments using non-specific IgG were unable to precipitate either tagged or endogenous nucleolin or Hdm2. (e) Hdm2 and nucleolin interact in vitro. Whole-cell extracts from HCT116-wt and -ko cells were incubated with beads containing GSTalone or GST-Hdm2. Following binding and extensive washing, the bead-bound material was analysed by SDS-PAGE and Western blotting for nucleolin and GST. To conserve space, the appropriate bands from GST-alone (lanes 1 and 2) and GST-Hdm2 (lanes 3 and 4) were spliced into a single panel.
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A Saxena et al nucleolin (compare endogenous and GFPNu in lane 6, lower panel). Because nucleolin has an effect on Hdm2 protein levels (described in greater detail below), we more rigorously tested the influence of nucleolin on Hdm2 auto-ubiquitination. H1299 cells were transfected with Hdm2, Ub-His and two different levels of nucleolin (Figure 7b ). Aliquots that contained equivalent total Hdm2 protein were removed from each lysate, and then analysed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting to determine the level of modified Hdm2. Using this approach, we observed that heightened expression of nucleolin resulted in a loss of the ubiquitinated form of Hdm2 (compares lanes 2 and 3 to control lane 1). We conclude that nucleolin inhibits the auto-ubiquitination activity of Hdm2, and this reduced ubiquitin ligase activity contributes to decreased p53 ubiquitination.
Nucleolin diminishes Hdm2 protein levels
As indicated above, nucleolin caused an apparent loss of Hdm2 protein, even though inhibiting Hdm2 autoubiquitination (a surprising observation because heightened auto-ubiquitination has been reported to destabilize Hdm2 (Stommel and Wahl, 2004) ). We therefore further characterized the effect of nucleolin on Hdm2 levels in various cell lines. Because endogenous Hdm2 levels are normally very low, cells were transfected with Hdm2 and various amounts of the nucleolin expression constructs. In U2-OS cells, increases in the level of nucleolin caused a drastic reduction in Hdm2 protein Figure 7 Nucleolin inhibits Hdm2 auto-ubiquitination and reduces Hdm2 levels in a p53-independent manner. (a, b) Lysates prepared from H1299 cells transfected with Hdm2, Ub-His and GFPNu plasmids (1 Â and 3 Â correspond to 0.25 and 0.75 mg of the GFPNu vector, respectively) were analysed for Hdm2 and nucleolin (lower panel) using specific antibodies. With higher nucleolin expression (i.e., an B2-fold increase in total nucleolin), Hdm2 poly-ubiquitinated products as well as total Hdm2 levels were decreased. In panel b, lysate samples used in lanes 4-6 of panel a were first normalized for total Hdm2 levels, and then again immunoblotted for Hdm2. Although the same blot image was used for upper and lower panels, the signal in the upper panel was digitally enhanced to more clearly show the Hdm2-ubiquitination products. (c) U2-OS and (d, e) H1299 cells were transfected with Hdm2 (300 ng) and GFPNu (panel c, 300, 600 and 900 ng; panel d, 25,100, 300, 600 and 900 ng; panel e, 100, 300, 600 and 900 ng). H1299 cells were either used as a p53-null cell line (panel d) or transfected with 3 Â -Flag p53 (25 ng; panel e). Cells were treated with 30 mM MG132 for 4 h prior to harvest, where indicated. Aliquots of the lysates were probed by Western blot for GFP (i.e., nucleolin), Hdm2 and b-actin.
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A Saxena et al levels ( Figure 7c , lanes 4-6), with Hdm2 found to be virtually undetectable at the highest level of nucleolin (lane 6). A similar decrease in Hdm2 protein levels was observed in H1299 cells, indicating that the presence of p53 was not required for nucleolin to mediate this effect (Figure 7d , compare lanes 4 and 9). To elucidate if the nucleolin-Hdm2 interaction is influenced by the presence of p53, we directly tested the effect of p53 (Figure 7e ). Nucleolin again diminished the level of Hdm2 to an almost undetectable amount (Figure 7e , compare lane 7 to lane 2). The downregulation of Hdm2 expression by nucleolin was similar in the presence or absence of p53. Interestingly, upon nucleolin overexpression, total Hdm2 protein accumulation was slightly reduced in the presence of MG132 (Figure 7c , compare lane 7 to lane 3; Figure 7e , compare lane 8 to lane 3). Experiments using cells in which nucleolin levels were downmodulated by RNA interference (RNAi) did not reveal any significant differences in Hdm2 stability compared to cells treated with a control siRNA (data not shown), perhaps indicating that nucleolin uses a mechanism distinct from control of Hdm2 stability to reduce Hdm2 levels. Overall, these data indicate that nucleolin reduces Hdm2 protein, with this reduction not strongly influenced by p53.
Nucleolin stimulates p53 transcriptional activity and inhibits cellular proliferation
Because changes in the level of nucleolin can alter the amount of p53 protein, we determined the effect of nucleolin on various p53-mediated activities, first testing p53 transcriptional activity in H1299 cells. Using p53-responsive elements from the promoters of the cyclindependent kinase (cdk) inhibitor p21 cip1/waf1 or Mdm2 genes, we found that nucleolin stimulated expression from 1.9-to 3.4-fold in the presence of p53 (Figure 8a) . Nucleolin in the absence of p53 had no significant effect. We also measured the expression of endogenous p21 cip1/ waf1 protein, and found that nucleolin increased the level of this key cell-cycle regulator (Figure 8b) . At the highest level of nucleolin, genotoxic stress did not markedly stimulate the expression of p53 or p21 cip1/waf1 protein ( Figure 8b, compare lanes 4 and 5) . Further, when the isogenic cell lines HCT116-wt and -ko were examined, higher levels of p21 cip1/waf1 were again seen following expression of GFP-nucleolin ( Figure 8c , lane 2). Only very low levels of p21 cip1/waf1 were observed in HCT116-ko cells expressing GFP-nucleolin (Figure 8c , lane 4), demonstrating that the stimulation is p53-specific. Similar results were noted for the proapoptotic Bax gene product (data not shown). Testing the effect of nucleolin on the genotoxic stress response, we found that nucleolin expression enhanced p53 activation at low levels of CPT as compared to the corresponding vector control (Figure 8d , compare lanes 2 and 3 with lanes 6 and 7, respectively). A corresponding increase in p21 levels was similarly noted in cells expressing GFPnucleolin compared to GFP alone. As CPT levels increased further, no significant differences in p53 and p21 levels was noted between these cells (lanes 4 and 8) . cip1/waf1 expression. (a) H1299 cells were transfected with GFPNu (nucleolin) and/ or 3 Â Flag p53 plasmids, as indicated, and the Hdm2-or p21-promoter reporter constructs driving expression of firefly luciferase. The fold-change in firefly luciferase activity is plotted relative to the level of Renilla luciferase in the same extracts. All transfections were performed in triplicates in two independent experiments. The data indicated that p53 stimulated transcription from the Mdm2 promoter with a Po0.05 confidence criteria ('*') using the paired Student's t-test. (b) Lysates of U2-OS cells transfected with increasing levels of GFPNu (100, 300 and 900 ng) were analysed for GFP (i.e., nucleolin), p53, p21 cip1/waf1 and b-actin by Western blotting. To generate a genotoxic stress response, cells were treated with 2 mM CPT for 90 min (lane 5). The data indicate that overexpression of nucleolin in U2-OS cells increases the protein level of the p53 transcriptional target gene product, p21 cip1/waf1 . (c) Isogenic cell lines HCT116-wt and -ko were transfected with either GFP or GFPNu. Lysates were then subjected to Western blotting to reveal p53, p21 cip1/waf1 , GFP and b-actin. Note that the GFP panel is spliced with the antibody recognizing GFP in lane 1 and GFP-nucleolin in lanes 2, 3 and 4. (d) U2-OS cells transfected with either GFPNu or GFPc were subjected to various concentrations of CPT (0.02, 0.2, 0.6 mM) for 4 h. The levels of p53, p21 cip1/waf1 , Hdm2 and b-actin in cellular lysates were then analysed by Western blotting. The data suggest that, at low levels of genotoxic stress, nucleolin enhances p53 activation, resulting in a parallel increase in p21 cip1/waf1 protein levels.
ARF-like properties of nucleolin A Saxena et al
As found above, Hdm2 levels were significantly reduced with nucleolin overexpression as compared the vectortransfected cells. These data indicate that upregulation of p53 levels by nucleolin can also lead to heightened expression of various p53-responsive genes. Because nucleolin increases p21 cip1/waf1 expression, we examined the effect of nucleolin expression on cell proliferation. As a simple indicator of proliferation, we expressed either GFP or GFP-nucleolin in U2-OS or SJSA cells, plated the cells at equal low densities, and then grew the cells under G418 selection (Figure 9a ). Visual inspection found that cells expressing GFPnucleolin had a clear growth disadvantage over cells expressing GFP. To quantitate this effect, we expressed nucleolin in HCT116-wt cells and observed that nucleolin inhibited cell growth to levels B60% of these same cells transfected with the empty vector (Figure 9b ). In contrast, nucleolin expression in HCT116-ko cells had lesser effect as compared to cells transfected with an empty vector control, with this residual effect potentially due to the ability of nucleolin to inhibit the replication factor RPA (Daniely and Borowiec, 2000; Wang et al., 2001; Kim et al., 2005) . These data indicate that heightened expression of nucleolin inhibits cell proliferation in a p53-dependent manner.
p53 regulates numerous genes involved in the cellular apoptotic program. We therefore determined if p53-mediated apoptosis was modulated by nucleolin. Stable clones of U2-OS cells were generated, which expressed either GFP-nucleolin or GFP alone. Interestingly, although cells were maintained under G418 selection, it was found that GFP-nucleolin expression was lost in B50% of cells following 2 weeks of growth, compared to B25% of cells losing GFP expression (data not shown). Following selection, the fraction of GFPpositive cells undergoing apoptosis was then examined using a TdT-mediated dUTP nick-end labeling (TU-NEL) assay (Figure 9c ). In all, 1500 cells were examined for each clone. Cells expressing GFP-nucleolin were found to have an B2-fold higher level of apoptosis (4.5%) compared to cells expressing GFP (2.5%). Our data indicate that heightened nucleolin expression can both inhibit cellular proliferation and increase apoptosis under normal growth conditions.
Discussion
The ability to increase p53 protein levels through binding and inhibition of the p53-antagonist Hdm2 implicates nucleolin as a key regulatory factor in the p53-Hdm2 circuitry. The consequences of elevated p53 levels are enhanced expression of p21 cip1/waf1 , a corresponding reduction of cellular proliferation rate and an increased rate of apoptosis. Importantly, the nucleolin gene contains a c-Myc binding site (E-box) in the first intron and nucleolin transcription is stimulated B4-fold by c-Myc, suggesting that it is directly responsive to proliferative signals (Greasley et al., 2000) . Indeed, nucleolin protein expression is coupled to the cellular growth rate, with proliferating cells having a >3-fold higher nucleolin protein levels compared to quiescent cells (e.g., see Sirri et al., 1997) . We observe significant effects on p53 levels when the amount of nucleolin is changed only B0.5-2-fold. Combined, these data indicate that nucleolin increases p53 protein levels in response to hyperproliferative signals, and thereby provide a check against uncontrolled cellular growth.
The number of parallels between nucleolin and the ARF tumor suppressor are striking. First, similar to the nucleolin properties that we have described, ARF expression is upregulated in response to proliferative Figure 9 Nucleolin inhibits cell proliferation and increases apoptosis in non-stressed cells. (a) (Upper two panels) U2-OS and SJSA cells expressing either GFPc or GFPNu were grown under G418 drug selection for B3 weeks. (Lower panel) Individual stable U2-OS clones expressing either GFP or GFPNu were plated at equal density and grown under selection for 21 days. Colony formation was viewed after staining with crystal violet. Quantitation of colonies formed in U2-OS stables indicated a 2.6-fold larger number of GFP colonies (n ¼ 216) as compared to colonies expressing GFP-nucleolin (n ¼ 83). (b) Transiently transfected HCT116-wt and -ko cells were harvested at 40, 48, 72, 96 and 120 h, and the cell density determined. The relative growth rates were determined at each time point, and averaged for each cell linetransfection combination. Use of the paired Student's t-test indicated that nucleolin inhibited growth in p53-expressing cells with a confidence level of Po0.01 ('**'). (c) The TUNEL assay was performed in U2-OS stable clones expressing either GFPc or GFPNu. In total, 1500 cells were carefully examined to determine cells that were positive for both GFP and TUNEL staining. signals (de Stanchina et al., 1998; Palmero et al., 1998; Radfar et al., 1998; Zindy et al., 1998) . At these elevated levels, ARF stabilizes p53 by associating with Mdm2 Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998) . Second, ARF inhibits the E3 ubiquitin ligase activity of Mdm2 (Honda and Yasuda, 1999; Midgley et al., 2000) , and has been reported to reduce Hdm2 levels (Zhang et al., 1998) . Third, both factors function in rRNA processing, although nucleolin is instrumental in facilitating an early cleavage event (Ginisty et al., 1998) , while p19 ARF inhibits downstream processing steps, likely by interference with the nucleophosmin/B23 endoribonuclease (Savkur and Olson, 1998; Itahana et al., 2003; Sugimoto et al., 2003; Bertwistle et al., 2004) . Fourth, as would be expected of proteins with ribosome biogenic functions, both nucleolin and ARF are primarily nucleolar (Ginisty et al., 1999; Zhang and Xiong, 1999; Weber et al., 2000) . Importantly, while ARF and nucleolin can associate (Weber et al., 2000) , our observed effects of nucleolin on Hdm2 activity and p53 protein levels are not dependent upon ARF because they can occur in cells that lack detectable p14ARF mRNA and protein expression. It is worth emphasizing that ARF-null cells can still raise p53 levels partially or completely when confronted with oncogenic stress, demonstrating the existence of ARFindependent mechanism(s) (de Stanchina et al., 1998; Zindy et al., 1998; Tolbert et al., 2002; Verschuren et al., 2002) . We hypothesize that nucleolin functions in such an ARF-independent pathway to regulate p53 and Hdm2 in response to hyperproliferative signals.
Because nucleolin has numerous activities in common with ARF, a reasonable question to ask is whether nucleolin is a tumor suppressor itself. While our data suggest that the answer to this question is likely to be yes, we are not aware of any cancer cells expressing nucleolin mutants. This may simply be a consequence of the critical role that nucleolin plays in rRNA maturation. Budding and fission yeasts deleted for the gene encoding a nucleolin homolog (NSR1 and gar2 þ , respectively) are viable, but show severe growth defects and have aberrant pre-rRNA processing (Kondo and Inouye, 1992; Lee et al., 1992; Gulli et al., 1995) . Similarly, our RNAi-mediated downmodulation of nucleolin causes toxic effects on cell viability (data not shown), likely resulting from an inability to properly process rRNA. These data indicate that mammalian cells lacking nucleolin will be non-viable, or at least have an extreme growth restriction. That said, it is conceivable that nucleolin mutants that have selective defects in the interactions with Mdm2 and p53 can be constructed and thus directly tested for their tumor suppressor properties.
We find that nucleolin binds Hdm2, inhibits its E3 ubiquitin ligase activity and reduces Hdm2 protein levels, and these collectively lead to an increase in p53 levels in non-stressed cells. Although we have previously observed that nucleolin can associate with the Cterminal domain of p53 (which is the target for ubiquitination (Rodriguez et al., 2000) ), nucleolin-p53 complex formation is minimal unless cells are subjected to genotoxic stress (Daniely et al., 2002) . Taken together, these data suggest that nucleolin regulates p53 by different pathways in unstressed cells compared to cells undergoing genotoxic stress. Nucleolin-Hdm2 complex formation can occur under normal unstressed conditions, even though their predominant subcellular localization is different (nucleolar vs nucleoplasmic, respectively). A similar paradox was noted previously in our analysis of complexes between nucleolin and RPA (Kim et al., 2005) , with the latter factor showing only weak localization to the nucleolus. Even so, use of fluorescence resonance energy transfer (FRET) demonstrated that RPA had significant association with particular nucleolin mutants in the nucleolus as well as the nucleoplasm. Because nucleolin is a highly mobile factor constantly shuttling from the nucleolus to nucleoplasm, association can also occur in the latter compartment. For Hdm2, like RPA, our immunoprecipitation studies suggest that the fraction of the nucleolin and Hdm2 pools interacting with each other is relatively small. Because we nevertheless find that nucleolin has effects on Hdm2 activity, this suggests that nucleolinHdm2 complex formation is predominantly transient in nature.
The ability of nucleolin to both inhibit Hdm2 autoubiquitination and cause a reduction in Hdm2 protein levels is surprising. Heightened Mdm2 auto-ubiquitination has been found to stimulate its degradation (Stommel and Wahl, 2004 ); yet we find that nucleolin both inhibits auto-ubiquitination and decreases Hdm2 protein levels. Because the effect of nucleolin can be partly reversed by use of a proteasomal inhibitor (MG132; Figure 7c and e), it is possible that nucleolin facilitates Hdm2 degradation even though preliminary results have not revealed any obvious effects of nucleolin overexpression or knockdown on Hdm2 half-life (data not shown). Other mechanisms are possible. Although nucleolin is predominantly a nucleolar protein, it constantly shuttles between the nucleus and cytoplasm (Borer et al., 1989) . Thus, it is possible that nucleolin aids Hdm2 export to the cytoplasm and stimulates its degradation. Because nucleolin regulates the stability of specific mRNAs (e.g., Bcl-2 and gadd45a; Sengupta et al., 2004; Zheng et al., 2005) , we do not rule out the possibility that nucleolin might also regulate translation of the Hdm2-encoding mRNA (as it regulates p53 translation following DNA damage in MCF7 cells; Takagi et al., 2005) or Hdm2 mRNA stability. The mechanism by which nucleolin inhibits the ubiquitin ligase activity of Hdm2 is similarly unclear. Complex formation with nucleolin may cause conformational changes in Hdm2 that inhibit the ubiquitin ligase reaction. Alternatively, the presence of nucleolin has the potential to sterically block the association of Hdm2 with the E2 ubiquitin-conjugating enzyme or p53. These and other possibilities are under investigation.
Previous data from our laboratory and others indicate that nucleolin can inhibit chromosomal DNA replication following heat shock and genotoxic stress via complex formation with the essential DNA replication factor RPA (Daniely and Borowiec, 2000; Wang et al., 2001; Kim et al., 2005) . Thus, nucleolin can regulate cell cycle progression both through a p53-independent pathway and the p53-dependent pathway described here. Recently, it has been shown that nucleolin inhibits translation of the p53 mRNA following DNA damage in MCF7 cells (Takagi et al., 2005) . Combined with the defined involvement of nucleolin in rRNA processing (Ginisty et al., 1998; Saez-Vasquez et al., 2004) , these findings show nucleolin to be a central factor that integrates critical cellular processes, including ribosome biogenesis, proliferation and the response to stress.
More generally, it is now becoming obvious that a number of proteins involved in ribosome biogenesis regulate Mdm2 activity or modulate the Mdm2-antagonist ARF. In addition to nucleolin, factors such as nucleophosmin/B23 (Itahana et al., 2003; Bertwistle et al., 2004; Kurki et al., 2004; Korgaonkar et al., 2005) and the large ribosomal subunits L5, L11 and L23 (Lohrum et al., 2003; Zhang et al., 2003; Bhat et al., 2004; Jin et al., 2004) have each been found to inhibit Mdm2. It has been estimated that pre-rRNA synthesis accounts for B40-60% of total cellular transcription (Hannan et al., 1998) , while more than half of total protein synthesis is devoted towards ribosome production (Moss, 2004) . Cellular transformation has been suggested to proceed in step with deregulated protein synthesis (see, e.g. Ruggero and Pandolfi, (2003) and references therein). It would not be unexpected that inordinately high demands for protein synthesis as found within incipient cancer cells would cause the induction of p53 as a barrier to inhibit tumor development. Thus, expressed elements of the ribosome biogenic machinery (ribo-proteome) conceivably serve as a signal to control cell proliferation and apoptosis through the p53 pathway.
Materials and methods
Nucleolin, p53 and Hdm2 expression vectors
The expression constructs for human nucleolin full length (aa 1-707) containing an N-terminal GFP-(GFPNu), Myc or Flag-tag were described previously (Kim et al., 2005) . To generate suitable vectors for stable expression in the HCT116 cell lines, the puromycin-resistance gene was cloned into GFPNu and GFPc (GFP-only; pEGFP-C1 from BD Biosciences Clontech, Mountain View, CA, USA) expression vectors. GST-Hdm2 was induced and expressed from Escherichia coli BL21 cells using the pGEX6P (Amersham Pharmacia, Piscataway, NJ, USA) vector. The Flag-p53 wt (human), Hdm2 wt and His 6 -tagged ubiquitin (Ub-His) constructs were kindly provided by M Oren (Weizmann Institute, Rehovot, Israel), B Vogelstein (John Hopkins University, Baltimore, MD, USA) and M Pagano (New York University School of Medicine, New York, NY, USA), respectively.
Antibodies
The primary antibodies used for immunoprecipitation or Western blotting were as follows: nucleolin, either the mouse monoclonal MS-3 or rabbit polyclonal H250 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); GFP, the rabbit polyclonal anti-GFP antibody (Molecular Probes, Carlsbad, CA, USA); p53, mouse monoclonal DO-1 (Santa Cruz Biotechnology); p53 phosphorylated on Ser15, rabbit polyclonal pS15p53 (Cell Signaling Technology, Danvers, MA, USA); p21, mouse monoclonal CIP1 (BD Biosciences Pharmingen, San Diego, CA, USA); and Hdm2, mouse monoclonal SMP14 (Santa Cruz Biotechnology) or Ab1 (Oncogene Res. Products, San Diego, CA, USA). Mouse monoclonal antibodies against GST, FLAG (M2) and b-actin were obtained from Sigma-Aldrich (St Louis, MO, USA). The secondary antibodies used were anti-mouse and anti-rabbit HRP-conjugated antibodies (Amersham), and fluorescent-conjugate antibodies (Jackson ImmunoResearch, West Grove, PA, USA).
Cell culture and transfection HCT116 p53-wt and -ko cell lines (Bunz et al., 1998) were kindly provided by Dr Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA). All other cell lines were obtained from ATCC. Plasmid transfections were performed using Effectene transfection reagent (Qiagen, Valencia, CA, USA). Nucleolin overexpression did not result in any significant changes to either the cellular or nucleolar appearance, and did not cause any apparent toxic effects on cells. When required, CPT (Sigma-Aldrich; a stock concentration of 10 mM in DMSO) was directly added to the growth media to a final concentration of 2 mM for 90 min. To determine the p53 half-life, HCT116-wt cells were transfected with either GFPc or GFPNu vectors. At 36 h post-transfection, cells were treated with cycloheximide (200 mg/ml), and harvested at various times. Lysates were prepared and analysed by Western blotting with anti-p53 antibodies (DO-1).
To generate stable cell lines, U2-OS cells were seeded at 5 Â 10 5 cells per 60-mm plate and transfected with 1 mg of GFPNu or 0.5 mg of GFPc vectors. Post-transfection (18 h), the cells were replated at the density of 10 4 cells/10 cm dish in duplicates. GFP-expressing cells were selected in McCoy's 5A media containing 400 or 800 mg/ml G418 (Cellgro) medium for 21 days, with the drug-containing media replaced every week. Individual clones were subsequently isolated and expanded over a 2-4-week period.
For nucleolin downmodulation experiments, siRNA duplexes (Dharmacon, Lafayette, CO, USA) corresponding to nucleolin positions 2215-2235 (siNu1) or 2292-2310 (siNu2; in the 3 0 untranslated sequence) were employed, using nucleolin sequence information from Accession NM_005381. U2-OS cells in 24-well plates were transfected with 200 nM of either siNu1 or siNu2, and then harvested at 24, 48 and 72 h posttransfection. Luciferase siRNA (siLuc) was used as a control. Immunofluorescence microscopy was performed as described by Vassin et al. (2004) .
Assay of p53 and Hdm2 ubiquitination Purification of His 6 -ubiquitinated p53 conjugates was performed essentially as described in Rodriguez et al. (1999) . Cells were processed 36 h post-transfection with 3 Â Flag-p53 and Hdm2 (at a ratio of 1:20), Ub-His, GFPNu and pBluescript pIIKS þ (the latter reagent used to equalize the total amount of DNA transfected). An aliquot of the cell suspension (20%) was directly used for Western blot analysis (see below). The remaining cells were lysed with denaturing buffer (6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 0.01 M TrisHCl, pH 8.0, 5 mM imidazole and 10 mM b-mercaptoethanol), the His-tagged ubiquitinated proteins purified on Ni 2 þ -NTAagarose beads (Qiagen), and then analysed by Western blotting using specific antibodies against p53.
For identifying the ubiquitinated Hdm2 species, H1299 cells were transfected for 24-36 h with Flag-Hdm2 and GFPNu (at ratios of 1:1-1:3), Ub-His and pBluescript pIIKS þ vectors.
When required, cells were treated with the proteasome inhibitor MG132 (30 mM; Calbiochem) for 4 h prior to harvest. Following washing with 1 Â phosphate-buffered saline (PBS), cells were lysed directly on 100 mm dishes in 50 mM Tris-HCl, pH 7.6, 0.5 mM ethylene diamine tetraacetate (EDTA), 1% (w/ v) SDS and 1 mM dithiothreitol (DTT), scraped into eppendorf tubes and boiled for 10 min. The concentration of the cell lysate was determined and Western blot analysis was performed with an anti-Hdm2 (SMP14) antibody.
In vitro ubiquitination was performed as described by Wang et al. (2002) . Reactions (15 ml) containing bacterially expressed human E1, E2 (GST-UbcH5), p53 (1 ml produced in a wheat germ transcription-coupled in vitro translation system (Promega, Madison, WI, USA)), GST-Mdm2 (400 ng) and 10 mg ubiquitin (Sigma), GST-nucleolin (Kim et al., 2005) , 1 mg/ml ATPgS (Boehringer, Ridgefield, CT, USA), 40 mM Tris-HCl, pH 7.5, 2 mM DTT, and 5 mM MgCl 2 were incubated for 60 min at 301C. Reactions were quenched by addition of 15 ml of SDS-PAGE buffer, boiled for 5 min and analysed by 8% SDS-PAGE and Western blotting with an anti-p53 antibody (DO-1).
Immunoprecipitation and GST-pulldown
Transfected cells were lysed in 20 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES), pH 7.4, 100 mM NaCl, 0.5% (v/v) Nonidet P (NP)-40, 10% (v/v) glycerol, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM Na 3 VO 4 , 1 mM NaF, and 1 mg per ml each of aprotinin, leupeptin and pepstatin. Cell extracts were incubated with the desired primary antibody for 2 h at 41C, and the immunocomplex captured using either protein A or protein G-plus beads at 41C overnight. The beads were then washed five times with BC100 buffer (20 mM Tris-HCl, pH 7.9, 0.1 mM EDTA, 10% glycerol, 100 mM KCl, 4 mM MgCl 2 , 0.2 mM PMSF, 1 mM DTT and 0.25 mg per ml of pepstatin), eluted with 2 Â SDS-PAGE lysis buffer and boiled for 10 min. The proteins were resolved by SDS-PAGE gels and analysed by Western blotting.
To evaluate Hdm2 and nucleolin binding in vitro, a GST pulldown assay was performed. GST-Hdm2 and GST-alone were purified to near homogeneity on glutathione-Sepharose beads. Whole-cell extracts were prepared from HCT116-wt and -ko cells in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% (v/v) NP-40, 1% (v/v) Triton X-100, 2 mM DTT, 2 mM PMSF and 1 mg per ml each of aprotinin, leupeptin and pepstatin). Prior to the binding assay, lysates were diluted 10-fold with lysis buffer containing 200 mM NaCl but lacking NP-40 and Triton X-100 (i.e., to reduce the NP-40 and Triton X-100 levels to 0.1% (v/v) each), and then pre-cleared thrice over the glutathione-Sepharose beads before being loaded onto the GST-Hdm2 or GST-alone affinity columns. An equivalent amount of GST-Hdm2-or GST-bound beads were loaded with equal amount of protein from HCT116-wt or -ko cell lysates and incubated at 41C overnight. The beads were washed extensively with 25 mM Tris-HCl, pH 7.8, 500 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% (v/v) glycerol, 0.2% (v/ v) NP-40, 1% (v/v) Triton X-100 and 0.1% sodium deoxycholate, and then equilibrated with 25 mM Tris-HCl, pH 7.8, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% (v/v) glycerol and 0.2% (v/v) NP-40 for loading. Proteins bound to the beads were analysed by Western using anti-nucleolin and anti-GST antibodies.
Western blot analysis
To visualize total cellular proteins, the cell suspension was pelleted and lysed in NP-40 lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, pH 8.0, 1% (v/v) NP-40, 2 mM DTT, 2 mM PMSF), and incubated on ice for 30 min. Lysates were similarly obtained from the Hdm2 ubiquitination experiments. Proteins were subjected to Western blot analysis using standard conditions and visualized using ECL-Plus (Perkin-Elmer, Wellesley, MA, USA). Digital images were analysed using Image SXM and ImageJ software. b-Actin was used for normalization when quantitating band intensities.
Transcription assays
Plasmids encoding firefly luciferase under the control of the p21 or Hdm2 promoter were kindly provided by M Oren. Briefly, p21 and Hdm2 promoter sequences (both of which contain a p53 response element) were amplified by PCR and ligated into pGL3-Basic reporter plasmid (Promega), upstream of the luciferase gene. H1299 cells were transfected with Flagp53 and/or GFPNu plasmids, along with either the p21-Luc or Hdm2-Luc reporter constructs. Renilla luciferase under the control of cytomegalovirus (CMV) promoter was cotransfected as a control. Cells were harvested 24 h post-transfection and luciferase assayed with a commercial double luciferase kit (Promega), employing a TD-20e luminometer (Turner BioSystems, Sunnyvale, CA, USA). Luciferase activities were normalized against the level of Renilla luciferase in the same extracts.
Proliferation assay
For visual examination of proliferation rates, U2-OS and SJSA cells stably transfected with GFPNu or GFPc cells were plated at constant density and grown for 3-4 weeks under G418 selection. Cells were fixed with 10% T-cell antigen for 10 min at room temperature, and then stained with crystal violet (0.5 in 80% methanol) for 15 min. For assessing the effect of nucleolin expression on growth rate, HCT116-wt and -ko cell lines were transiently transfected with Flag-nucleolin or empty Flag vectors. At 24 h post-transfection, cells were counted and replated at equivalent densities into 96-well plates in triplicate. Cells were harvested at different time points (40, 48, 72, 96 and 120 h post-transfection) and stained with 0.1% crystal violet in 80% methanol. After the cells were washed thoroughly with 1 Â PBS, the crystal violet was eluted in absolute ethanol and measured at 600 nm in a 96-plate reader (Dynatech MR7000) as a measure of cell density. The experiment was performed on three independent occasions in triplicate. The relative growth rates were determined at each time point and averaged. TUNEL Apoptosis was assayed by TUNEL using the In Situ Cell Death Detection Kit (TMR Red; Roche, Indianapolis, IN, USA) following the manufacturer's protocol. Following endlabeling, the cells were viewed by fluorescence microscopy to visualize the TUNEL stain, GFP and Hoechst. GFPc-or GFPNu-positive cells with either complete or granular nuclear TUNEL staining were considered as positive apoptotic cells. In total, 1500 cells were counted for each construct. 
